Expansion to three active C anadian sites marks a key milestone in advancing Trichomylin® softgel capsules into later-stage trials
SASKATOON, SK, Oct. 2, 2025 /CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the activation of two additional clinical sites in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial. The addition of CancerCare Manitoba ("CCMB") and The Research Institute of the McGill University Health Centre ("The Institute"), along with the Centre Hospitalier de l'Université de Montréal ("CHUM"), expands the Phase 2a UPOPIA-1 trial to three active clinical sites across Canada.
UTOPIA-1 is a single-arm, proof-of-concept study designed to evaluate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With three active sites, the trial is positioned to broaden diversity of trial participants and accelerate patient enrollment in the Phase 2a UTOPIA-1 trial evaluating Trichomylin® softgel capsules.
"Expanding the UTOPIA-1 trial to three clinical sites marks a meaningful step forward in our mission to deliver safer, scientifically validated alternatives that have the potential to improve patient outcomes," said Brent Zettl, President and CEO of ZYUS Life Sciences. "The activation of these two additional clinical sites strengthens our clinical development program and advances our path toward generating preliminary efficacy and safety data needed to progress Trichomylin® softgel capsules into later-stage trials."
For more information about the Phase 2a UTOPIA-1 trial, please visit clinicaltrials.gov and reference identifier NCT06533657.
About ZYUS Life Sciences Corporation
ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit www.zyus.com or follow us on X @ZYUSCorp.
Cautionary Note Regarding Forward-Looking Statements
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that serve as alternatives to current pain management therapies such as opioids, the timing of activation of additional clinical trial sites, enrollment of patients in UTOPIA-1, the Company's ability to demonstrate safety and efficacy of its drug candidate and bring to market innovative therapies for pain management, commercialization of innovative therapies for pain management, and the Company's beliefs regarding potential shareholder value. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and to introduce products that serve as alternatives to current pain management therapies such as opioids, the timing of activation of additional clinical trial sites, enrollment of patients in UTOPIA-1, the Company's ability to demonstrate safety and efficacy of its drug candidate and bring to market innovative therapies for pain management, commercialization of innovative therapies for pain management, and the Company's beliefs regarding potential shareholder value are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE ZYUS Life Sciences Corporation
